Loading...
•
Dec 31, 2023
Bioventus Q4 2023 Earnings Report
Announced fourth quarter and full year financial results, demonstrating sales growth and improved profitability.
Key Takeaways
Bioventus reported a 7.6% increase in worldwide revenue for the fourth quarter, driven by strong organic growth in Pain Treatments and Surgical Solutions. The company's net loss decreased compared to the prior year, and adjusted EBITDA improved due to revenue growth and cost management. Full-year revenue remained consistent with the previous year, with growth in Surgical Solutions.
Accelerated fourth quarter sales growth to 7.6%, with organic growth of 14.3%.
Rob Claypoole was appointed as President and Chief Executive Officer.
Net loss from continuing operations improved to $7.7 million compared to $35.4 million in the prior-year period.
Adjusted EBITDA from continuing operations increased by 28.1% to $22.0 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bioventus introduced its financial guidance for full-year 2024.
Positive Outlook
- Net sales of $520 million to $535 million
- Adjusted EBITDA of $89 million to $94 million
- Non-GAAP EPS of $0.12 to $0.20
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...